DioGenix uses state-of-the-art genomics technologi

DioGenix uses state-of-the-art genomics technologies and sophisticated biostatistics to quickly identify and validate novel panels of genomic biomarkers that represent “gene signatures”. A gene signature is a panel of genomic biomarkers whose pattern of gene expression correlates with disease status. They can be used to 1) provide disease diagnosis and prognosis; 2) predict disease progression and regression; and 3) predict and monitor a patient’s response to therapy. Optimally, the biomarkers included in a gene signature will be associated with multiple biological networks that are affected in the disease being studied. One can think of a gene signature as a unique molecular fingerprint. Since genomic biomarkers measure changes in biological processes at the molecular level, they can more accurately identify and differentiate similar diseases and disease subtypes, even when patients display very similar clinical symptoms. Gene signatures form the groundwork for the development of critically needed MDx assays and improve patient management for difficult-to-manage diseases like MS and TM. They also may be used as key components in future theranostic applications to facilitate the delivery of the right drug to individual patients, based on the individual patient’s own genomic profile.

DioGenix evolved out of Gene Logic, a leading Genomics Service company with more than 10 years experience generating high-quality genomics data and building comprehensive genomics databases including BioExpress®. BioExpress® is a comprehensive database of human genomic and clinical information. It contains “whole-genome” expression profiles for more than 12,000 clinical samples covering more than 400 different disease types. DioGenix maintains a close working relationship with Gene Logic with preferred access to BioExpress®, in addition to their extensive clinical network, biorepository and genomics data production lab.

DioGenix is leveraging this relationship and has established new relationships with clinical experts and prominent organizations in the MS and TM research communities, including Dr. Benjamin Greenberg, Director of the Johns Hopkins Encephalitis Center and Co-Director of the Johns Hopkins Transverse Myelitis Center; The Accelerated Cure Project for Multiple Sclerosis (ACP) and The Transverse Myelitis Association (TMA).